Cost-effectiveness of sumatriptan in a managed care population

American Journal of Managed Care

Volumn 3, Issue 1, 1997, Pages 117-122

  Legg, Randall F ^a   Sclar, David A ^a,b   Nemec, Neil L ^a   Tarnai, John ^b   Mackowiak, John I ^c  

^a Qual Med Health Plan of Washington Inc   (United States)

^b WASHINGTON STATE UNIVERSITY   (United States)

^c Center for Outcomes Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SUMATRIPTAN; VASOCONSTRICTOR AGENT;

ARTICLE; COST BENEFIT ANALYSIS; COST OF ILLNESS; DRUG COST; ECONOMICS; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; MIGRAINE; OUTCOME ASSESSMENT; STATISTICS; UNITED STATES; UTILIZATION REVIEW;

COST OF ILLNESS; COST-BENEFIT ANALYSIS; DRUG COSTS; HEALTH EXPENDITURES; HUMANS; INDEPENDENT PRACTICE ASSOCIATIONS; MIGRAINE DISORDERS; OUTCOME ASSESSMENT (HEALTH CARE); SUMATRIPTAN; VASOCONSTRICTOR AGENTS; WASHINGTON;

EID: 0030628845     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Stewart WF, Lipton RB, Celentano DD, Reed ML. Prevalence of migraine headache in the United States. JAMA 1992;267:64-69.
2. Lipton RB, Stewart WF, Celentano DD, et al. Undiagnosed migraine headaches: A comparison of symptom based and reported physician diagnosis. Arch Intern Med 1992;152:1273-1278.
3. Close JC, Osterhaus JT. Healthcare resource use and costs associated with migraine in a managed healthcare setting. Ann Pharmacother 1994;28:659-664.
4. Osterhaus JT, Gutterman DL, Plachetka JR. Healthcare resource and lost labour costs of migraine in the US. PharmacoEconomics 1992;2:67-76.
5. Skaer TL. Clinical presentation and treatment of migraine. Clin Ther 1996;18:229-245.
6. Greiner DL, Addy SN. Sumatriptan use in a large group-model health maintenance organization. Am J Health-Syst Pharm 1996;53:633-638.
7. Streator SE, Shearer SW. Pharmacoeconomic impact of injectable sumatriptan on migraine associated healthcare costs. Am J Man Care 1996;2:139-143.
8. Legg RF. How an HMO-Industry partnership has produced successful outcomes data: a migraine case study. Presented at the Zitter Group meeting; December 1995; Washington, DC.
9. Cleary PD, Jette AM. The validity of self reported physician utilization measures. Med Care 1994;22:796-803.
10. Weeks MF, Kulka RA, Lessler JT, Whitmore RW. Personal versus telephone surveys for collecting household data at the local level. Am J Public Health 1983;73:1389-1394.
11. Drummond MF, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. Oxford, England: Oxford University Press; 1986.
12. The Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. N Engl J Med 1991;325:316-321.
13. Tansey MJB, Pilgrim AJ, Lloyd K. Sumatriptan in the acute treatment of migraine. J Neurol Sci 1993;114:109-116.
14. Deming WE. Out of the Crisis. Cambridge, MA: Massachusetts Institute of Technology, Center for Advanced Engineering Study; 1993.